Servier Laboratories and CTI agree collaboration for marketing Pixuvri outside US.
Servier Laboratories and CTI BioPharma Corp.,jointly announced that they have entered into an exclusive license and collaboration agreement to develop and commercialize Pixuvri (pixantrone). Pixuvri is conditionally approved in the European Union for patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who failed two or three prior lines of therapy. Pixuvri is the first monotherapy treatment option for this patient group and the only therapy licensed for third and fourth line use in aggressive B-cell NHL patients, which includes diffuse large B-cell lymphoma (DLBCL).
As of this announcement, Pixuvri was available in 11 countries and has achieved reimbursement decisions in England/Wales, Italy, France, Germany and the Netherlands. CTI retains full commercialization rights for Pixuvri in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, the UK and the US, with Servier having exclusive rights to commercialize Pixuvri in all other countries.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins